Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Contribution

The Sensitivity and Specificity of Monoclonal Antibodies URO-2 and 19-9 in the Immunohistochemical Classification of Primary Adenocarcinomas

Daniel D. Sedmak, M.D. and Raymond R. Tubbs, D.O.
Cleveland Clinic Journal of Medicine September 1986, 53 (3) 277-282;
Daniel D. Sedmak
Department of Pathology, Ohio State University College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond R. Tubbs
The Cleveland Clinic Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The specificity and sensitivity of commercially available monoclonal antibodies (McAb) to tumor antigens were tested using McAb 19-9, derived from a colorectal adenocarcinoma, and URO- 2, derived from a renal adenocarcinoma. Using the avidin-biotincomplex technique and frozen tissue, 53 adenocarcinomas representing lung, breast, colorectal, ovarian, renal, and uterine origin were studied. All slides were randomized and subsequently evaluated for staining intensity and percent tumor-area positivity. The sensitivity and specificity of 19-9 for colorectal adenocarcinoma were 74% and 54%, respectively. The sensitivity and specificity of URO-2 for renal adenocarcinoma were 100% and 87.5%, respectively. In most cases, URO-2 stained greater than 75% of the renal tumor area; however, 19-9 stained less than 50% of the colorectal tumor area.

Index terms
  • Adenocarcinoma
  • classification
  • Antibodies
  • monoclonal
  • Received November 1985.
  • Accepted February 1986.
  • Copyright © 1986 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 53 (3)
Cleveland Clinic Journal of Medicine
Vol. 53, Issue 3
21 Sep 1986
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Sensitivity and Specificity of Monoclonal Antibodies URO-2 and 19-9 in the Immunohistochemical Classification of Primary Adenocarcinomas
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Sensitivity and Specificity of Monoclonal Antibodies URO-2 and 19-9 in the Immunohistochemical Classification of Primary Adenocarcinomas
Daniel D. Sedmak, Raymond R. Tubbs
Cleveland Clinic Journal of Medicine Sep 1986, 53 (3) 277-282;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Sensitivity and Specificity of Monoclonal Antibodies URO-2 and 19-9 in the Immunohistochemical Classification of Primary Adenocarcinomas
Daniel D. Sedmak, Raymond R. Tubbs
Cleveland Clinic Journal of Medicine Sep 1986, 53 (3) 277-282;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A good death: is euthanasia the answer?
  • Diagnosis and treatment of panic disorder
  • Benzodiazepines in the treatment of movement disorders
Show more Contribution

Similar Articles

Keywords

  • Adenocarcinoma
  • classification
  • Antibodies
  • Monoclonal

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire